United Kingdom · Question · Written question
UIN 689
Tixagevimab/cilgavimab
Original
Introduced
11 May 2022
Last action
17 May 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 May 2022
Summary
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 28 April 2022 to Question 141960, what progress has been made on assessing Evusheld for treating immunocompromised patients.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
11 May 2022
Written question
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 28 April 2022 to Question 141960, what progress has been made on assessing Evusheld for treating immunocompromised patients.
Source: Commons
17 May 2022
Answer
The UK Health Security Agency has yet to complete testing on Evusheld’s efficacy against the Omicron variant. The timing of these results is dependent on the testing assays being completed successfully, which will inform any decisions on potential deploym...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-05-11/689
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1462000
- uk · wq-1462000 · source updated 17 May 2022